Skip Navigation

Eligible for a Dupixent lawsuit?

Lawsuit Alleges Dupixent Eczema Treatment Triggered Cutaneous T-Cell Lymphoma

Lawsuit Alleges Dupixent Eczema Treatment Triggered Cutaneous T-Cell Lymphoma

An Indiana man has filed a lawsuit alleging the makers of Dupixent failed to adequately warn patients and doctors about evidence suggesting the popular eczema treatment could cause or accelerate certain forms of skin cancer.

The complaint (PDF) was brought by Anthony Simerman in the U.S. District Court for the District of New Jersey on November 11, naming Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC and Genzyme Corporation as defendants.

Dupixent Cancer Risks

Dupixent (dupilumab) received U.S. Food and Drug Administration (FDA) approval in 2017 to treat moderate to severe atopic dermatitis, commonly known as eczema. Since then, regulators have authorized the medication for several additional inflammatory conditions, including asthma and chronic obstructive pulmonary disease (COPD).

The expanded indications have helped make Dupixent one of the world’s best-selling medications, generating approximately $17.6 billion in global revenue in 2025, with quarterly sales of more than $6 billion in the third quarter of 2026.

However, research published in recent years has raised concerns about a possible association between Dupixent side effects and certain types of T-cell lymphoma, particularly cutaneous T-cell lymphoma (CTCL), a rare cancer that primarily affects the skin. Diagnosing CTCL can be difficult because its early symptoms often resemble eczema and other inflammatory skin conditions for which Dupixent is prescribed.

The findings have prompted a number of Dupixent cancer lawsuits nationwide, alleging the manufacturers failed to adequately disclose the potential lymphoma risks to patients and physicians. Plaintiffs maintain that stronger warnings could have prompted doctors to prescribe alternative medications or more closely monitor patients for early signs of CTCL, potentially allowing the cancer to be detected and treated sooner.

Dupixent-Lawsuit
Dupixent-Lawsuit

Dupixent CTCL Allegations

According to the complaint, Simerman was prescribed Dupixent in April 2022 to treat atopic dermatitis, commonly known as eczema. He used the medication as directed through August 2022, after receiving promotional materials about the treatment, including a Dupixent brochure.

In February 2026, approximately three and a half years after discontinuing Dupixent, Simerman was diagnosed with cutaneous T-cell lymphoma (CTCL), also known as mycosis fungoides. The lawsuit indicates he has since required extensive medical treatment, including oral medications and chemotherapy, and has been advised that he will likely need ongoing care indefinitely.

Simerman alleges Dupixent caused or accelerated his cancer, claiming the manufacturers knew or should have known about the lymphoma risks before he began treatment. However, the companies allegedly failed to warn patients and physicians or recommend appropriate testing and monitoring to detect early signs of CTCL.

The complaint also points to a March 31, 2025, FDA report identifying CTCL as a potential safety signal associated with Dupixent, which the agency indicated warranted further evaluation. Although the finding did not establish a causal connection, Simerman maintains the manufacturers continued marketing the medication without adequately updating its cancer warnings.

“But for Defendants’ failure to provide a clear warning regarding the increased risk of CTCL with the use of Dupixent, Plaintiff’s physician would not have prescribed her Dupixent and Plaintiff, Anthony Simerman, would not have taken Dupixent to treat his atopic dermatitis.”

— Anthony Simerman v. Regeneron Pharmaceuticals Inc.

The filing raises allegations of failure to warn, negligence, fraudulent misrepresentation, negligent misrepresentation and breach of express warranty. It seeks more than $75,000 in compensatory damages, as well as punitive damages, medical expenses, lost earnings and compensation for pain, suffering and other losses.

Dupixent Cancer Lawsuits

Simerman’s complaint was filed directly into the federal Dupixent multidistrict litigation (MDL No. 3180), which currently includes approximately 40 similar Dupixent cancer lawsuits pending before U.S. District Judge Zahid N. Quraishi in the District of New Jersey.

The cases have been centralized for coordinated discovery and pretrial proceedings, with the number of claims expected to grow as more individuals diagnosed with cutaneous T-cell lymphoma (CTCL) investigate whether their cancer may be linked to Dupixent use.

As the litigation moves forward, the court may establish a series of early bellwether trials, in which representative cases are presented to juries to help the parties evaluate how evidence and testimony common to the lawsuits may be received.

Although the outcomes of these trials would not be binding on other plaintiffs, they could influence potential Dupixent settlement negotiations. If the litigation is not resolved through settlements or other proceedings, Simerman’s case and other individual claims may eventually be returned to their designated federal courts for separate trials.

Sign up for more legal news that could affect you or your family.

Michael Adams
Written By: Michael Adams

Senior Editor & Journalist

Michael Adams is a senior editor and legal journalist at AboutLawsuits.com with over 20 years of experience covering financial, legal, and consumer protection issues. He previously held editorial leadership roles at Forbes Advisor and contributes original reporting on class actions, cybersecurity litigation, and emerging lawsuits impacting consumers.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

About 100 different plaintiffs have filed a lawsuit alleging Amazon served as the storefront for multiple illicit nitrous oxide dealers, leading to severe injuries and addiction.

About the writer

Michael Adams

Michael Adams

Michael Adams is a senior editor and legal journalist at AboutLawsuits.com with over 20 years of experience covering financial, legal, and consumer protection issues. He previously held editorial leadership roles at Forbes Advisor and contributes original reporting on class actions, cybersecurity litigation, and emerging lawsuits impacting consumers.